

<b>Name</b>	<b>Lenz, Georg, Univ.-Prof. Dr. med.</b>
Address:	University Hospital of Münster, Department of Internal Medicine A, Albert-Schweitzer-Campus 1, 48149 Münster, Germany Phone: +49-251-83-47587
Position:	Professor, Director of Department of Internal Medicine A, University Hospital of Münster
<b>Scientific career</b>	
11/2021	President elect of the German Lymphoma Alliance (GLA)
Since 2017	Member of the Steering Committee of the German Lymphoma Alliance (GLA)
2017-2021	Speaker of the High grade lymphoma working group of the German Lymphoma Alliance (GLA)
Since 2020	Scientific Director of the Westdeutsches Tumorzentrum, Standortpartner Münster
Since 08/2017	Director of Department of Hematology, Oncology, and Pneumology, University Hospital of Münster
2016-2017	Speaker of the “Early Trials Network” study group
2014-2017	W3 Professorship and Head of the “Translational Oncology Unit” at the University Hospital of Münster
2013-2014	Senior leading physician (Leitender Oberarzt) in the Department of Hematology, Oncology and Tumor Immunology at the Charité - Universitätsmedizin Berlin, Germany
2012-2014	Deputy Director and Scientific Coordinator of the „Berlin School of Integrative Oncology“ graduate school that was funded by the Excellence Initiative of the German federal and state governments
2012-2013	Senior physician in the Department of Hematology, Oncology and Tumor Immunology at the Charité - Universitätsmedizin Berlin, Germany
2009	Appointment as Assistant professor on the “Molecular Pathogenesis of malignant Lymphomas” at the Charité - Universitätsmedizin Berlin
2009-2014	Principal investigator at the Department of Hematology, Oncology and Tumor Immunology at the Charité - Universitätsmedizin Berlin, Germany
2005-2009	Postdoctoral research fellow in the Laboratory of Dr. Louis Staudt at the Lymphoid Malignancies Section, Metabolism Branch at the National Cancer Institute, Bethesda, USA
2002-2005	Assistant physician at the Department of Internal Medicine III Hematology/Oncology at the Klinikum Grosshadern at the Ludwig-Maximilians Universität, Munich, Germany
<b>Honors/ Awards</b>	
11/2013	Monika Kutzner Award for Cancer Research
11/2013	Together with Daniel Krappmann and colleagues: Paula und Richard von Hertwig-Preis für interdisziplinäre Zusammenarbeit, Helmholtz Zentrum Munich
10/2013	Artur-Pappenheim Award of the German Society of Hematology and Oncology (DGHO)
10/2009	World Health Summit & Pfizer Award

### Peer review responsibilities (selection)

- Editor: Annals of Hematology, Cancer Treatment Reviews
- Reviewer scientific journals: Annals of Oncology, Blood, Cancer Research, Cell Reports, Clinical Cancer Research, Genome Biology, Journal of Clinical Investigation, Journal of Clinical Oncology, Lancet Hematology, Lancet Oncology, Leukemia, Nature Clinical Practice Oncology, Nature Communications, Nature Medicine, Oncogene, PLOS Genetics, PNAS, Science Immunology, Science Signaling, Science Translational Medicine, Scientific reports
- Reviewer scientific meetings: Annual meeting of the American Society of Hematology, Annual meeting of the European Hematology Association, International Conference on Malignant Lymphoma, Annual meeting of the German Society of Hematology and Oncology, ESH conferences
- Reviewer for the following funding organizations: Belgian Foundation against Cancer, Berlin Institute of Health, Cancer Research UK, Czech Health Research Council, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Else Kröner-Fresenius-Stiftung, Helmholtz Gemeinschaft, Italian Association for Cancer Research, José Carreras Leukämie-Stiftung, Kay Kendall Leukemia Fund, Leukaemia & Lymphoma Research, Margarete von Wrangell-Habilitationsprogramm, PMU Research Fund Salzburg, Research Grants Council Hong Kong, Wilhelm Sander-Stiftung, Tiroler Wissenschaftsfonds

### Guideline activities

2021	First and leading author of the Diffuse large B-cell lymphoma (DLBCL) Onkopedia Guideline
2021	Co-author of the German S3-Guideline on Diffuse large B-cell lymphoma (DLBCL)
2021	Co-author of the 5th edition of the WHO Classification of Haematolymphoid Tumours
2021	Member of the Clinical Advisory Committee (CAC) for disease classifications of leukemias and lymphomas

### Additional responsibilities

2021	Co-Chair of the ESH Conference „New Concepts in Lymphoid Malignancies“
2021	Co-Chair of the AACR Conference „AACR Virtual Meeting: Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma (DLBCL)“
2021	Chair of the 7th German Lymphoma Forum
2019	Co-Chair of the 6th German Lymphoma Forum

2019	Co-Chair of the ESH Conference „New Concepts in Lymphoid Malignancies“ in Estoril
2018	Co-Chair of the ESH Conference „New Concepts in Lymphoid Malignancies“ in Dublin
2016-2018	Election into the „Scientific Committee“ of the European School of Haematology (ESH)
Since 2015	Organizer of three „Münsteraner Lymphom-Symposium“
2013 + 2014	Co-organizer of the „Berlin Lymphom Symposium“
Since 2013	Member of the „Program committee“ „NHL Aggressiv“ of the German Society of Hematology and Oncology (DGHO)

## Patents

2009	„Predicting survival outcome of a subject from suffering DLBCL by determining germinal center B cell signature value and stromal-1 signature value from a gene expression profile to calculate survival predictor score“
------	--

## Publication record (status 10/2021)

Citations: more than 13.000 citations

h-index: 47

Author of more than 175 peer-reviewed articles among other in leading journals such as The New England Journal of Medicine, Nature, Science, Nature Medicine, Nature Genetics, Nature Immunology, Cancer Cell, Journal of Clinical Oncology, and Blood.

## 10 most important Publications

1. Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, Berning P, Wullenkord R, Erdmann T, Lutz M, Veratti P, Ehrenfeld S, Wienand K, Horn H, Goodlad JR, Wilson MR, Anagnostopoulos I, Lamping M, Gonzalez-Barca E, Climent F, Salar A, Castellvi J, Abrisqueta P, Menarguez J, Aldamiz T, Richter J, Klapper W, Tzankov A, Dirnhofer S, Rosenwald A, Mate JL, Tapia G, Lenz P, Miething C, Hartmann W, Chapuy B, Fend F, Ott G, Navarro JT, Grau M, **Lenz G**. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. *Nat Commun*. 2021 Aug 31; 12 (1): 5183.
2. **Lenz G**, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, Ardeshtna K, Chong G, Haaber J, Shi W, Gorbachevsky I, Lippert S, Hiemeyer F, Piraino P, Beckmann G, Peña C, Buvaylo V, Childs BH, Salles G. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. *Leukemia*. 2020 Aug; 34 (8): 2184-2197.
3. Grau M, **Lenz G**, Lenz P. Dissection of gene expression datasets into clinically relevant interaction signatures via high-dimensional correlation maximization. *Nat Commun*. 2019 Nov 28; 10 (1): 5417.
4. Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR,

- Cruzalegui F, Trneny M, Lenz P, Barry ST, **Lenz G**. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. *Blood*. 2017 Jul 20; 130 (3): 310-322.
5. Dai B, Grau M, Juilland M, Kleiner P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, **Lenz G**. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. *Blood*. 2017 Jan 19; 129 (3): 333-346.
  6. Weilemann A, Grau M, Erdmann T, Merkel O, Sobhifshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, **Lenz G**. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. *Blood*. 2015 Jan 1; 125 (1): 124-32.
  7. Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chunchan F, Meissner B, Bhang H, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey M, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, **Lenz G\***, Stegmeier F\*. Pharmacological and genomic profiling identifies NFκB-targeted treatment strategies for mantle cell lymphoma. *Nature Medicine*. 2014 Jan; 20 (1): 87-92. **\*Equally contributing last and corresponding author.**
  8. Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dirnhofer S, Lenz P, Hummel M, Tzankov A, **Lenz G**. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. *PNAS*. 2013 Jul 23; 110 (30): 12420-5.
  9. **Lenz G**, Wright G,...,Staudt LM. Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med*. 2008 Nov 27; 359 (22): 2313-23.
  10. **Lenz G\***, Davis RE\*, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*. 2008 Mar 21; 319 (5870): 1676-9.
- \*Equally contributing first author.**